Subanalysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk study investigated the efficacy of evolocumab vs. placebo for reducing CV events in a subset of statin-treated patients with prior stroke (36). This evidence concerns the gene PCSK9 and Stroke.